Details for Patent: 11,160,792

Which drugs does patent 11,160,792 protect, and when does it expire?

Patent 11,160,792 protects VIBERZI and is included in one NDA.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 11,160,792

Title:	Opioid receptor modulator dosage formulations
Abstract:	Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Inventor(s):	Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
Assignee:	Allergan Holdings ULC
Application Number:	US17/211,274
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,160,792
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 11,160,792

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No	11,160,792		Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes	11,160,792		Y

International Family Members for US Patent 11,160,792

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014241076
Brazil	112015022753
Canada	2906472
Canada	3254178
China	105228629